Filing Flows › Lifevantage (LFVN) › Q3 2026 › vs Q3 2025
Lifevantage (LFVN) Q3 2026 vs Q3 2025 (year over year)
Lifevantage's revenue fell $10.4M (-22%) from $47.6M in Q3 2025 to $37.1M in Q3 2026. The biggest changes: Life Vantage Product Line −$5.5M (-53%); Protandim −$4.1M (-18%); True Science Product Line −$2.3M (-23%).
Lifevantage, Q3 2026: revenue $37.1M (-22% year over year), operating margin -0.4%, net loss $196K, operating cash flow $533K. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Protandim | $18.0M | $22.1M | −$4.1M | -18% |
| True Science Product Line | $7.6M | $9.9M | −$2.3M | -23% |
| Life Vantage Product Line | $4.8M | $10.3M | −$5.5M | -53% |
| AXIO Product Line | $2.9M | $3.5M | −$592K | -17% |
| Product and Service Other | $1.7M | $1.4M | $379K | +28% |
| Love Biome Product Line | $1.7M | $0 | $1.7M | — |
| Phys IQ Product Line | $500K | $1.2M | −$700K | -58% |
| Revenue | $37.1M | $47.6M | −$10.4M | -22% |
| Net loss | $196K | −$2.2M | $2.4M | — |
| Costs & expenses | $37.3M | $47.6M | −$10.2M | -22% |
| Operating costs | $37.3M | $45.3M | −$8.0M | -18% |
| Income tax | $12K | $86K | −$74K | -86% |
| Cost of revenue | $9.1M | $9.7M | −$597K | -6% |
| Research & development | $200K | $300K | −$100K | -33% |
| SG&A | $12.7M | $14.9M | −$2.1M | -14% |
| Other operating costs | $15.2M | $20.4M | −$5.2M | -26% |
| Operating cash sources | $1.0M | $1.4M | −$400K | -28% |
| Depreciation & amortization | $730K | $610K | $120K | +20% |
| Share-based compensation | $306K | $826K | −$520K | -63% |
| Net loss absorbed | $196K | −$2.2M | $2.4M | — |
| Working capital & other | $307K | $5.9M | −$5.6M | -95% |
| Operating cash flow | $533K | −$2.3M | $2.8M | — |
| Capital expenditures | $1.2M | $439K | $801K | +182% |
| Negative free cash flow (OCF − capex) | $707K | $2.7M | −$2.0M | -74% |
Questions
How much did Lifevantage's revenue grow year over year in Q3 2026?
Lifevantage's revenue fell $10.4M (-22%) from $47.6M in Q3 2025 to $37.1M in Q3 2026.
What drove Lifevantage's revenue change in Q3 2026?
Life Vantage Product Line −$5.5M (-53%); Protandim −$4.1M (-18%); True Science Product Line −$2.3M (-23%).